{"name":"Chinese Academy of Medical Sciences","slug":"chinese-academy-of-medical-sciences","ticker":"","exchange":"","domain":"cams.ac.cn","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"immunology","drugs":[{"name":"Anlotinib combined with pemetrexed and carboplatin, phase II","genericName":"Anlotinib combined with pemetrexed and carboplatin, phase II","slug":"anlotinib-combined-with-pemetrexed-and-carboplatin-phase-ii","indication":"Other","status":"phase_1"},{"name":"MSC+ATG","genericName":"MSC+ATG","slug":"msc-atg","indication":"Other","status":"marketed"},{"name":"pemetrexed plus cisplatin","genericName":"pemetrexed plus cisplatin","slug":"pemetrexed-plus-cisplatin","indication":"Other","status":"marketed"},{"name":"singular","genericName":"singular","slug":"singular","indication":"Other","status":"marketed"},{"name":"Anlotinib combined with paclitaxel and carboplatin, phase I","genericName":"Anlotinib combined with paclitaxel and carboplatin, phase I","slug":"anlotinib-combined-with-paclitaxel-and-carboplatin-phase-i","indication":"Other","status":"phase_1"},{"name":"EC-T","genericName":"EC-T","slug":"ec-t","indication":"Other","status":"phase_2"},{"name":"Experimental: Rivaroxaban monotherapy","genericName":"Experimental: Rivaroxaban monotherapy","slug":"experimental-rivaroxaban-monotherapy","indication":"Other","status":"marketed"},{"name":"Naoxintong Capsule","genericName":"Naoxintong Capsule","slug":"naoxintong-capsule","indication":"Angina pectoris","status":"marketed"},{"name":"Tranexamic Acid Dosage 1","genericName":"Tranexamic Acid Dosage 1","slug":"tranexamic-acid-dosage-1","indication":"Prevention and treatment of hemorrhage in surgical procedures","status":"marketed"},{"name":"Tranexamic Acid Dosage 2","genericName":"Tranexamic Acid Dosage 2","slug":"tranexamic-acid-dosage-2","indication":"Other","status":"marketed"},{"name":"bOPV(Liquid)","genericName":"bOPV(Liquid)","slug":"bopv-liquid","indication":"Prevention of poliomyelitis","status":"phase_3"},{"name":"live attenuated Japanese encephalitis vaccine","genericName":"live attenuated Japanese encephalitis vaccine","slug":"live-attenuated-japanese-encephalitis-vaccine","indication":"Prevention of Japanese encephalitis","status":"marketed"},{"name":"two measles attenuated live vaccine","genericName":"two measles attenuated live vaccine","slug":"two-measles-attenuated-live-vaccine","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Adjuvant chemotherapy for experimental group","genericName":"Adjuvant chemotherapy for experimental group","slug":"adjuvant-chemotherapy-for-experimental-group","indication":"Adjuvant treatment in experimental oncology trial (specific cancer type not specified)","status":"phase_3"},{"name":"Experimental: mXELOX plus cetuximab","genericName":"Experimental: mXELOX plus cetuximab","slug":"experimental-mxelox-plus-cetuximab","indication":"Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type)","status":"phase_3"},{"name":"Active Comparator: FOLFOX plus cetuximab","genericName":"Active Comparator: FOLFOX plus cetuximab","slug":"active-comparator-folfox-plus-cetuximab","indication":"Metastatic colorectal cancer, KRAS wild-type","status":"phase_3"},{"name":"Camrelizumab and Apatinib","genericName":"Camrelizumab and Apatinib","slug":"camrelizumab-and-apatinib","indication":"Hepatocellular carcinoma","status":"phase_3"},{"name":"Docetaxel;oxaliplatin;s1","genericName":"Docetaxel;oxaliplatin;s1","slug":"docetaxel-oxaliplatin-s1","indication":"Advanced or metastatic gastric cancer","status":"phase_3"},{"name":"Epirubicin, CTX, Paclitaxel","genericName":"Epirubicin, CTX, Paclitaxel","slug":"epirubicin-ctx-paclitaxel","indication":"Breast cancer (likely early-stage or metastatic, based on typical EC-P regimen use)","status":"phase_3"},{"name":"Epirubicin, Paclitaxel","genericName":"Epirubicin, Paclitaxel","slug":"epirubicin-paclitaxel","indication":"Breast cancer (early-stage and metastatic)","status":"phase_3"},{"name":"Idarubicin(IDA)","genericName":"Idarubicin(IDA)","slug":"idarubicin-ida","indication":"Acute myeloid leukemia (AML)","status":"marketed"},{"name":"Irinotecan Injection","genericName":"Irinotecan Injection","slug":"irinotecan-injection","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Paclitaxel and carboplatin","genericName":"Paclitaxel and carboplatin","slug":"paclitaxel-and-carboplatin","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Platinum-Based Drug","genericName":"Platinum-Based Drug","slug":"platinum-based-drug","indication":"Various solid tumors (specific indication in phase 3 trial not specified)","status":"phase_3"},{"name":"oxaliplatin;s1","genericName":"oxaliplatin;s1","slug":"oxaliplatin-s1","indication":"Treatment of metastatic colorectal cancer","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"Active Comparator: Aspirin+Clopidogrel","genericName":"Active Comparator: Aspirin+Clopidogrel","slug":"active-comparator-aspirin-clopidogrel","indication":"Acute coronary syndrome","status":"marketed"},{"name":"Active Comparator: Rivaroxaban+Clopidogrel","genericName":"Active Comparator: Rivaroxaban+Clopidogrel","slug":"active-comparator-rivaroxaban-clopidogrel","indication":"Acute coronary syndrome with high thrombotic risk","status":"marketed"},{"name":"Amlodipine, Telmisartan, Amiloride Compound , Simvastatin","genericName":"Amlodipine, Telmisartan, Amiloride Compound , Simvastatin","slug":"amlodipine-telmisartan-amiloride-compound-simvastatin","indication":"Hypertension with dyslipidemia","status":"marketed"},{"name":"Experimental: Aspirin monotherapy","genericName":"Experimental: Aspirin monotherapy","slug":"experimental-aspirin-monotherapy","indication":"Secondary prevention of cardiovascular events (myocardial infarction, stroke)","status":"marketed"},{"name":"Qishenyiqi dropping pills","genericName":"Qishenyiqi dropping pills","slug":"qishenyiqi-dropping-pills","indication":"Angina pectoris","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"bOPV(Candy)","genericName":"bOPV(Candy)","slug":"bopv-candy","indication":"COVID-19 prevention","status":"phase_3"},{"name":"OM-85 BV","genericName":"OM-85 BV","slug":"om-85-bv","indication":"Prevention of recurrent respiratory tract infections","status":"marketed"},{"name":"pegylated filgrastim and filgrastim","genericName":"pegylated filgrastim and filgrastim","slug":"pegylated-filgrastim-and-lgrastim","indication":"Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy","status":"phase_3"},{"name":"filgrastim and pegylated filgrastim","genericName":"filgrastim and pegylated filgrastim","slug":"lgrastim-and-pegylated-filgrastim","indication":"Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy","status":"phase_3"}]}],"pipeline":[{"name":"Adjuvant chemotherapy for experimental group","genericName":"Adjuvant chemotherapy for experimental group","slug":"adjuvant-chemotherapy-for-experimental-group","phase":"phase_3","mechanism":"Adjuvant chemotherapy uses cytotoxic drugs administered after primary treatment to eliminate residual cancer cells and reduce recurrence risk.","indications":["Adjuvant treatment in experimental oncology trial (specific cancer type not specified)"],"catalyst":""},{"name":"Anlotinib combined with pemetrexed and carboplatin, phase II","genericName":"Anlotinib combined with pemetrexed and carboplatin, phase II","slug":"anlotinib-combined-with-pemetrexed-and-carboplatin-phase-ii","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Experimental: mXELOX plus cetuximab","genericName":"Experimental: mXELOX plus cetuximab","slug":"experimental-mxelox-plus-cetuximab","phase":"phase_3","mechanism":"mXELOX plus cetuximab combines modified capecitabine/oxaliplatin chemotherapy with an EGFR-targeting monoclonal antibody to inhibit tumor cell proliferation and survival.","indications":["Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type)"],"catalyst":""},{"name":"MSC+ATG","genericName":"MSC+ATG","slug":"msc-atg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bOPV(Candy)","genericName":"bOPV(Candy)","slug":"bopv-candy","phase":"phase_3","mechanism":"bOPV(Candy) is a vaccine that targets the SARS-CoV-2 virus.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"pemetrexed plus cisplatin","genericName":"pemetrexed plus cisplatin","slug":"pemetrexed-plus-cisplatin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"singular","genericName":"singular","slug":"singular","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active Comparator: Aspirin+Clopidogrel","genericName":"Active Comparator: Aspirin+Clopidogrel","slug":"active-comparator-aspirin-clopidogrel","phase":"marketed","mechanism":"Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events.","indications":["Acute coronary syndrome","Secondary prevention after myocardial infarction","Stroke prevention in patients with recent ischemic stroke or transient ischemic attack","Prevention of stent thrombosis after percutaneous coronary intervention"],"catalyst":""},{"name":"Active Comparator: FOLFOX plus cetuximab","genericName":"Active Comparator: FOLFOX plus cetuximab","slug":"active-comparator-folfox-plus-cetuximab","phase":"phase_3","mechanism":"FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition.","indications":["Metastatic colorectal cancer, KRAS wild-type","Locally advanced colorectal cancer"],"catalyst":""},{"name":"Active Comparator: Rivaroxaban+Clopidogrel","genericName":"Active Comparator: Rivaroxaban+Clopidogrel","slug":"active-comparator-rivaroxaban-clopidogrel","phase":"marketed","mechanism":"This combination uses rivaroxaban (a Factor Xa inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.","indications":["Acute coronary syndrome with high thrombotic risk","Stroke prevention in atrial fibrillation with acute coronary syndrome"],"catalyst":""},{"name":"Amlodipine, Telmisartan, Amiloride Compound , Simvastatin","genericName":"Amlodipine, Telmisartan, Amiloride Compound , Simvastatin","slug":"amlodipine-telmisartan-amiloride-compound-simvastatin","phase":"marketed","mechanism":"This fixed-dose combination reduces blood pressure and cardiovascular risk through calcium channel blockade, angiotensin II receptor antagonism, potassium-sparing diuresis, and cholesterol lowering.","indications":["Hypertension with dyslipidemia","Cardiovascular risk reduction in hypertensive patients"],"catalyst":""},{"name":"Anlotinib combined with paclitaxel and carboplatin, phase I","genericName":"Anlotinib combined with paclitaxel and carboplatin, phase I","slug":"anlotinib-combined-with-paclitaxel-and-carboplatin-phase-i","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Camrelizumab and Apatinib","genericName":"Camrelizumab and Apatinib","slug":"camrelizumab-and-apatinib","phase":"phase_3","mechanism":"Camrelizumab blocks PD-1 to enhance immune response while apatinib inhibits VEGFR2 to suppress tumor angiogenesis, combining immunotherapy with anti-angiogenic effects.","indications":["Hepatocellular carcinoma","Gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Docetaxel;oxaliplatin;s1","genericName":"Docetaxel;oxaliplatin;s1","slug":"docetaxel-oxaliplatin-s1","phase":"phase_3","mechanism":"This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously.","indications":["Advanced or metastatic gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"EC-T","genericName":"EC-T","slug":"ec-t","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epirubicin, CTX, Paclitaxel","genericName":"Epirubicin, CTX, Paclitaxel","slug":"epirubicin-ctx-paclitaxel","phase":"phase_3","mechanism":"This is a combination chemotherapy regimen where epirubicin and paclitaxel are topoisomerase II and microtubule-targeting agents respectively, used together to inhibit cancer cell division and induce apoptosis.","indications":["Breast cancer (likely early-stage or metastatic, based on typical EC-P regimen use)"],"catalyst":""},{"name":"Epirubicin, Paclitaxel","genericName":"Epirubicin, Paclitaxel","slug":"epirubicin-paclitaxel","phase":"phase_3","mechanism":"Epirubicin and paclitaxel are chemotherapy agents that work together to inhibit cancer cell division and induce apoptosis through different mechanisms.","indications":["Breast cancer (early-stage and metastatic)","Gastric cancer","Ovarian cancer"],"catalyst":""},{"name":"Experimental: Aspirin monotherapy","genericName":"Experimental: Aspirin monotherapy","slug":"experimental-aspirin-monotherapy","phase":"marketed","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","indications":["Secondary prevention of cardiovascular events (myocardial infarction, stroke)","Primary prevention of cardiovascular disease in high-risk patients"],"catalyst":""},{"name":"Experimental: Rivaroxaban monotherapy","genericName":"Experimental: Rivaroxaban monotherapy","slug":"experimental-rivaroxaban-monotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Idarubicin(IDA)","genericName":"Idarubicin(IDA)","slug":"idarubicin-ida","phase":"marketed","mechanism":"Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia in blast crisis"],"catalyst":""},{"name":"Irinotecan Injection","genericName":"Irinotecan Injection","slug":"irinotecan-injection","phase":"phase_3","mechanism":"Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death.","indications":["Metastatic colorectal cancer","Small cell lung cancer","Ovarian cancer","Gastric cancer"],"catalyst":""},{"name":"Naoxintong Capsule","genericName":"Naoxintong Capsule","slug":"naoxintong-capsule","phase":"marketed","mechanism":"Naoxintong Capsule is a traditional Chinese medicine formulation that improves blood circulation and reduces blood stasis to treat cardiovascular and cerebrovascular conditions.","indications":["Angina pectoris","Myocardial infarction prevention and treatment","Cerebral infarction and stroke prevention"],"catalyst":""},{"name":"OM-85 BV","genericName":"OM-85 BV","slug":"om-85-bv","phase":"marketed","mechanism":"OM-85 BV is a bacterial lysate immunostimulant that enhances innate and adaptive immune responses to prevent respiratory tract infections.","indications":["Prevention of recurrent respiratory tract infections","Recurrent sinusitis","Recurrent otitis media","Recurrent bronchitis"],"catalyst":""},{"name":"Paclitaxel and carboplatin","genericName":"Paclitaxel and carboplatin","slug":"paclitaxel-and-carboplatin","phase":"phase_3","mechanism":"Paclitaxel and carboplatin work together as a chemotherapy combination: paclitaxel stabilizes microtubules to prevent cell division, while carboplatin cross-links DNA to cause cell death.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer","Other solid tumors (phase 3 dependent on specific indication)"],"catalyst":""},{"name":"Platinum-Based Drug","genericName":"Platinum-Based Drug","slug":"platinum-based-drug","phase":"phase_3","mechanism":"Platinum-based drugs form covalent crosslinks with DNA, preventing replication and transcription to induce cancer cell death.","indications":["Various solid tumors (specific indication in phase 3 trial not specified)"],"catalyst":""},{"name":"Qishenyiqi dropping pills","genericName":"Qishenyiqi dropping pills","slug":"qishenyiqi-dropping-pills","phase":"marketed","mechanism":"Qishenyiqi dropping pills is a traditional Chinese medicine formulation that enhances cardiac function and improves blood circulation to support heart health.","indications":["Angina pectoris","Heart failure","Cardiac insufficiency"],"catalyst":""},{"name":"Tranexamic Acid Dosage 1","genericName":"Tranexamic Acid Dosage 1","slug":"tranexamic-acid-dosage-1","phase":"marketed","mechanism":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.","indications":["Prevention and treatment of hemorrhage in surgical procedures","Management of excessive bleeding in trauma and medical conditions"],"catalyst":""},{"name":"Tranexamic Acid Dosage 2","genericName":"Tranexamic Acid Dosage 2","slug":"tranexamic-acid-dosage-2","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bOPV(Liquid)","genericName":"bOPV(Liquid)","slug":"bopv-liquid","phase":"phase_3","mechanism":"bOPV is a live attenuated vaccine.","indications":["Prevention of poliomyelitis"],"catalyst":""},{"name":"live attenuated Japanese encephalitis vaccine","genericName":"live attenuated Japanese encephalitis vaccine","slug":"live-attenuated-japanese-encephalitis-vaccine","phase":"marketed","mechanism":"This live attenuated vaccine stimulates immune responses against Japanese encephalitis virus by introducing a weakened form of the virus that replicates but does not cause disease.","indications":["Prevention of Japanese encephalitis"],"catalyst":""},{"name":"oxaliplatin;s1","genericName":"oxaliplatin;s1","slug":"oxaliplatin-s1","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.","indications":["Treatment of metastatic colorectal cancer","Treatment of advanced gastric cancer"],"catalyst":""},{"name":"pegylated filgrastim and filgrastim","genericName":"pegylated filgrastim and filgrastim","slug":"pegylated-filgrastim-and-lgrastim","phase":"phase_3","mechanism":"Pegylated filgrastim and filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection.","indications":["Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy","Reduced infection risk in patients undergoing hematopoietic stem cell transplantation"],"catalyst":""},{"name":"two measles attenuated live vaccine","genericName":"two measles attenuated live vaccine","slug":"two-measles-attenuated-live-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"filgrastim and pegylated filgrastim","genericName":"filgrastim and pegylated filgrastim","slug":"lgrastim-and-pegylated-filgrastim","phase":"phase_3","mechanism":"Filgrastim and pegylated filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection.","indications":["Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy","Reduced infection risk in patients undergoing myeloablative chemotherapy or radiation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPV3kwd3NqWGtXdkh1U25jdG1pa0M1SzhPOXpQa1pHQjRseEVfeGFqSXphWmJzSDJkVmh6NkFPcXhFbW5xTk8tUXVjTmI5ajR4LTQ2V3QyRG93ZVB0UHpaZlJlbE82OFJsSkcxLTQ2UHhlZ3lrWlFHa0tpczZzWHVEanh4eUhnMmF4OG1QeFl2el91NUhrN1d4U0t4b05NLTRaQTBCdUd4ZW5MS3VWejJySjBuZVNHTUdwWVBqM0hBSENyanpIVFpMZ0w1eHNNN2F1ZTduYQ?oc=5","date":"2026-03-09","type":"earnings","source":"Yicai Global","summary":"CPPCC Members Propose Deepening China's Health System Reform to Boost Innovative Drug Profits - Yicai Global","headline":"CPPCC Members Propose Deepening China's Health System Reform to Boost Innovative Drug Profits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBKRkhyUXJFV3Brd1JZeHktRkdxY2Z5ODFIUmo1RG11UWd6SVdPUnFzWjkySXdTeDh3V3QwXzlhYzVPbHFaNEJNSWpfOVBxOFZIZGxpM1JEMzlXejZKMlpURVN0Zm5JTkxPQVByYWtoWEZxQjVxbXU0Ui1qUExZZw?oc=5","date":"2026-03-08","type":"pipeline","source":"China Daily","summary":"Action pledged to build healthy China - China Daily","headline":"Action pledged to build healthy China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1IdUduYW94WjViV25oeldEdEpycExJeERLRHZKZnFqLUI4MjRVS19iNUQ0OGNTcmd6QmxPWmhiUktoSWUxZUNhMmIzaGo3eU9jNURJbXducVRKWmNDUjAycncxbTVKWHFRRUhfUUNmRnNoS2QtTkFBVVkyRk5JZw?oc=5","date":"2025-12-26","type":"pipeline","source":"China Daily","summary":"Pharma innovations gain traction abroad - China Daily","headline":"Pharma innovations gain traction abroad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPekpGNk5HSzFZNDNGWU5lQUh1UUFfbnVVQzdVSVVkRlVHX1Z6YWxVLWh3d19QSTZ2QVRta09IZHNLS0NOODhsSkJIVnk2ellwR0ZOcHcyZHRxblF5ZVBUUXVwcDFLdDViQWdCOTRDRkRUdVNTQmFYMDg4SlN1SDRUQUtoMGJ3OUxFZnp2TUdqSW1FQi1Xbnd2eTlIQ21hd0ZQWTdnc21NekZKMFkyb1UzZFVhalcya3pKd1FBa1ZTZzRkUkMtQzBNTTZaR0ZDUEdfMURUeEwteUZ4WXBrR3UxYkc5cGFRMkt1TXhDMHQyZDcwZDBtQmxQaw?oc=5","date":"2025-12-25","type":"deal","source":"BioPharma APAC","summary":"HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework - BioPharma APAC","headline":"HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framewor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0ybElUMGpCVkQ1eFluT1FHcVhHRGZoQ1A0WHBCNDZraDJNd3VRLVFZR0FLZnhiTGQ4YkE2OTdENHpGX2FjR3dzUi1GUlFHZ3dEOEdBQzZ1dmtfYTJGdW1v?oc=5","date":"2025-12-23","type":"trial","source":"nature.com","summary":"TCMEval-PA: a question-answering benchmark dataset for the prescription audit of Traditional Chinese Medicine - nature.com","headline":"TCMEval-PA: a question-answering benchmark dataset for the prescription audit of Traditional Chinese Medicine","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-04","type":"pipeline","source":"South China Morning Post","summary":"China’s drug developers stretch to become a global force - South China Morning Post","headline":"China’s drug developers stretch to become a global force","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE81dzR6VXl2azJhLUNOcmRUSzRPTFZOTGJ3UlRnbGptN200YVhhb3FvMHA4OHdPejhEdU9vUGVUb3pvLVAzU0VtbXVlUDFvcGp1THJHWklwb2FFWXpaaF9tTQ?oc=5","date":"2025-09-05","type":"pipeline","source":"复宏汉霖","summary":"FUTUONING Sets Sail Commercially with First Prescriptions Across China-Media - 复宏汉霖","headline":"FUTUONING Sets Sail Commercially with First Prescriptions Across China-Media - 复宏汉霖","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQU1c5QWt0THU4WkNKR0ZuWVA5WXRucG0xdThfbERHelIwazRYYzVXMV9MYmhUTVBOSDhWLWNLZVhSRi1NNXVyOHhiMWJkcHV3SVdaZTlSVDZjT3NJTEduZHMtZDdhVkR6LWNPQWhIRXhSWXdkTmRoUmN5ZzVMLUlqaVAxcjR1cFpXX3RuZG5aVTVKWE1POXc?oc=5","date":"2025-09-01","type":"pipeline","source":"The Lancet","summary":"Establishing the China–UK Cancer Prevention and Control Alliance - The Lancet","headline":"Establishing the China–UK Cancer Prevention and Control Alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQU2U1Skw4OWdteDZvNVBKYlJuMk81WFhXNFh0bnlwOGx4Rm9Tb3JWRVZTTDNzSVlnSmNMMXNSdWdBTXRnSnF5NjJZQkVPWnJTNmhpdTA0Q0VJc2Rkb0VXWWU1WmU5TkxXdEV5Nk1SdkZ4T2duMFRNVU5hSUJLd0pkZnZKdVo1OVVZRmV1ZVhmcjhHcUFSVVFIZno2RU9wT1VqUnJMSlBzcw?oc=5","date":"2025-08-19","type":"patent","source":"JUVE Patent","summary":"Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent","headline":"Gilead attacks remdesivir patent of Chinese research institute at UPC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5CLVRlZVplRXVHVTVnWUpxTUNhWVBjMHFqRjlYQnpPbXROQ1pmXzBiXzlraXpzcDNwWGZFUmd3VWZLT05PdlI2N1d4UTlQUVdyV2prZkZmUmpIODNZMEhJ?oc=5","date":"2025-08-07","type":"trial","source":"nature.com","summary":"The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial - nature.com","headline":"The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized control","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFB5U3BOVnVaLXpSUTlRSnMtMk5kYjJKdGxhWVZBdGx5ajZ5OGZYeXNuMlFqcUJkYW1CSVEzRlB4N2FRTnR5OUtIQjMzeFg3Q1FLOU1zR3dJVVlMUm9jLXJDZHg2amNVaVJBYlQw?oc=5","date":"2024-03-06","type":"trial","source":"Wiley Online Library","summary":"Unveiling quality of clinical trial in China: from concern to confirmation - Huang - 2024 - Cancer Communications - Wiley Online Library","headline":"Unveiling quality of clinical trial in China: from concern to confirmation - Huang - 2024 - Cancer Communications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPODJKSXZZR1hzelNIdnVyeTdpbFh4Q1FtZXFINndjbHhGVnFZaWp0TzVLUW5Tbi1FWmo4dC1McW1UcDVIeWN5UEp1V3V5YTZRTVZIWjdZd1ZUbFV3V2hOOVh1dFk4ai1uQTNOMHBibFF6bTU5anY0azBKT1JadkVkV3VKa25yWmc0a2hNdzl3OVZJOEl3?oc=5","date":"2023-03-01","type":"pipeline","source":"Frontiers","summary":"A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019 - Frontiers","headline":"A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019","sentiment":"neutral"}],"patents":[],"drugCount":34,"phaseCounts":{"phase_3":15,"phase_1":2,"marketed":16,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}